Children and adolescents infected with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are predominantly asymptomatic or have mild symptoms compared with the …

Worldwide, over 694 million people have been infected with SARS-CoV-2, with an estimated
55–60% of those infected developing COVID-19. Since the beginning of the pandemic in …

Summary In this Personal View, we discuss current knowledge on SARS-CoV-2 RNA or
antigen persistence in children infected with SARS-CoV-2. Based on the evidence that the …

In rare instances, pediatric SARS-CoV-2 infection results in a novel immunodysregulation
syndrome termed multisystem inflammatory syndrome in children (MIS-C). We compared …

Abstract Purpose of Review To review the spectrum of cardiac manifestations and
treatments of multisystem inflammatory syndrome in children (MIS-C) associated with …

Background Inborn errors of immunity (IEI) and autoantibodies to type I interferons (IFNs)
underlie critical COVID-19 pneumonia in at least 15% of the patients, while the causes of …

Abstract Purpose of Review We highlight the new clinical entity multisystem inflammatory
syndrome in children (MIS-C), the progress in understanding its immunopathogenesis, and …

Multisystem inflammatory syndrome in children (MIS-C) is a delayed-onset, COVID-19-
related hyperinflammatory illness characterized by severe acute respiratory syndrome …

Background Autopsy studies have provided valuable insights into the pathophysiology of
COVID-19. Controversies remain about whether the clinical presentation is due to direct …

Multisystem inflammatory syndrome in children (MIS‐C) is a rare, but severe complication of
coronavirus disease 2019 (COVID‐19). It develops approximately 4 weeks after severe …